Table 2.
Study outcomes.
| Source | N= (# of AERD patients that completed the study) | Subjective Outcomes | Objective Outcomes | Follow up (months) |
|---|---|---|---|---|
| Adappa et al | 30 | SNOT-22 Scores mean (95% CI;p-value) | Revision Surgery Rate: | 30 |
| Preop: 47.0 (39.0–55.1) | 3/32 (9.4%) | |||
| 4 weeks postop: 15.2 (7.3–23.1; p < 0.001 comparing preop to postop SNOT-22) | ||||
| 1 month post-DS: 20.7 (12.1–29.3; p = 0.241 comparing preop to postop 1 month) | ||||
| 6 months post-DS: 21.0 (12–30; p = 0.245) | ||||
| 12 months post-DS: 17.2 (8.8–25.6; p = 0.669) | ||||
| 18 months post-DS: 26.2 (16.7–35.7; p = 0.037) | ||||
| 24 months post-DS: 22.3 (12.8–31.0; p = 0.188) | ||||
| 30 months post-DS: 22.6 (11.6–33.7; p = 0.218) | ||||
| Cho et al. | 21 | SNOT-22 Scores: mean (standard deviation;p-value) | Endoscopic polyp Score: Mean (SD) | 30 |
| Preop: 53.4 (12.4) | Preop: 5.6 (1.2) | |||
| 1 week postop: 14.5 (4.5; p = 0.042 preop-postop) | 1 week postop: 0.3 (0.5) (p < 0.001) preop-postop) | |||
| 4 weeks postop: 11.6 (2.5; p = 0.046 comparing preop to 4 weeks postop) | 4 weeks postop: 0.6 (0.8) (p = 0.001 comparing preop to 4 weeks postop) | |||
| 1 month post-DS: 11.0 (2.3) | 1 month post-DS: 0.5 (0.9) | |||
| 6 months post-DS: 9.2 (2.1) | 6 months post-DS: 0.3 (0.7) | |||
| 12 months post-DS: 8.9 (1.7) | 12 months post-DS: 0.6 (0.7) | |||
| 18 months post-DS: 8.6 (1.8) | 18 months post-DS: 0.8 (0.5) | |||
| 24 months post-DS: 8.7 (1.6) | 24 months post-DS: 0.7 (0.5) | |||
| 30 months post-DS: 8.9 (1.7) | 30 months post-DS: 0.6 (0.4) | |||
| Fruth et al | 31 | Quality of life questionnaire: median | Nasal polyposis Score: Median | 36 |
| (18/31 aspirin group, | Aspirin group: 46.0 | Aspirin group: 0 | ||
| 13/31 placebo group) | Placebo group: 68.6 | Placebo group: 2 | ||
| P = 0.0324 | P = 0.0702 | |||
| Overall nasal and paranasal complaints: mean | Recurrence of polyps | |||
| Aspirin: 4.3 | Aspirin group: 5/18 (28%) | |||
| Placebo: 2.4 | Placebo group: 8/13 (62%) | |||
| P = 0.0019 | P = 0.0785 | |||
| Quality of life impairment by nasal and sinus complaints: mean | Revision Surgery Rate | |||
| Aspirin: 4.0 | Aspirin group: 2/18 | |||
| Placebo:2.4 | Placebo group: 6/13 | |||
| P = 0.0083 | ||||
| General health condition: mean | ||||
| Aspirin:2.2 | ||||
| Placebo: 3.3 | ||||
| P = 0.029 | ||||
| Havel et al | 89 (56 aspirin desensitized, 33 surgery alone) |
QoL scores(18 months AD; 18 month ND) Nasal obstruction 1.77; 2.58 Rhinorrhea 2; 2.35 Post nasal drip 2; 2.58 Sneezing 1.96; 1.93 Sense of smell 2.94; 3.55 Snoring 2; 2.03 Dry Mouth 1.56; 2.48 Hoarse throat 1.32; 1.53 Facial pain 1.54; 2.21 Short breath 1.87; 1.97 Chest tightness 1.64; 1.69 Dyspnea 1.5; 1.45 Cough 1.57; 1.86 Sleep disturbance 1.6; 2.43 Frustrated 1.73; 2.4 Irritable 1.67; 2.3 Sad 1.43; 2.13 Tissue use 2.16; 2.87 |
Endoscopy Score Preop: 5.6 ± 1.2 Postop: 0.6 ± 0.4 Surgery alone group Postop: 1.0 ± 0.18 |
18 |
| McMains and Kountakis | 15 | SNOT-20 Scores | Nasal endoscopy scores: | 24 |
| (5 aspirin desensitized, 10 surgery alone) | AD group | AD Group: | ||
| Preop: 32.0 ± 3.6 | Preop: 7.6 ± 1.3 | |||
| Postop: 7.3 ± 1.7 | Postop: 1.1 ± 0.4 | |||
| Surgery alone group | Surgery alone group | |||
| Preop: 31.8 ± 3.9 | Preop: 7.6 ± 1.2 | |||
| Postop: 8.8 ± 1.7 | Postop: 2.0 ± 0.4 | |||
| Revision Surgery Rate | ||||
| AD Group: | ||||
| 0/5 | ||||
| Surgery alone group | ||||
| 8/10∗ (p = 0.003) | ||||
| Shah et al | 24 |
Rhinoconjunctivitis QoL score (preop; postop;pvalue) 2.5; 0.7; p < 0.001 Asthma Control Test (preop; postop;pvalue) 22; 19.5; p = 0.1 |
Nasal Peak Flow (preop; postop;pvalue) 140; 100; p = 0.01 FeNO (preop; postop;pvalue) 45; 38; p < 0.05 |
6 |